One study showed that stimulation of dendritic cells carrying this variant of SSc with a TLR2 agonist increased macrophage activation, resulting in increased production of interleukin-6 (IL-6) and tumor necrosis factor (46), thus participating in the pathogenesis of SSc. This evidence concerns the gene IL6 and systemic sclerosis.